Comparing Current Therapeutic Modalities of Androgenic Alopecia: A Literature Review of Clinical Trials

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This review suggests that stem cells might be a promising addition or alternative to standard treatments for androgenic alopecia, but larger studies are needed to confirm these findings.

This study found that platelet lysate significantly improved hair growth and follicle performance in both experimental settings and AGA patients, showing results comparable to platelet-rich plasma.

This review summarizes trichoscopic features for diagnosing common hair loss disorders and reports no new clinical results, emphasizing their diagnostic utility in conditions like alopecia areata and trichotillomania.

This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This study found that while both cetirizine 1% and minoxidil 5% increased hair density in men with androgenetic alopecia, minoxidil showed a significantly higher improvement, and both treatments lost effectiveness after 8 weeks without use; cetirizine was well-tolerated with no significant adverse reactions.

In this overview, the authors note that both pharmacologic and nonpharmacologic treatments are effective for pattern hair loss, emphasizing early detection and intervention to maintain hair.

This study found that combining platelet-rich plasma therapy with minoxidil was more effective in treating androgenetic alopecia in men than either treatment alone.

In this randomized clinical trial, the authors reported that adipose-derived stem cell constituent extract topical solution increased hair density and thickness in patients with androgenetic alopecia over 16 weeks compared to placebo.

This study reported that combined oral finasteride and topical 5% minoxidil treatment in men with male-pattern hair loss improved hair growth by initiating anagen in pre-existing but deficient follicles, yet the growth rates remained unchanged and did not normalize hair productivity.

This pilot study found that platelet-rich plasma injections did not improve hair growth in men with androgenetic alopecia.

In this study of patients with androgenetic alopecia, botulinum toxin type A was found to significantly increase hair counts and improve hair density and coverage, with enhanced results observed when combined with oral finasteride, revealing a safe and effective treatment approach without adverse effects.

This study found that platelet-rich plasma combined with topical minoxidil was more effective in increasing hair density for male-type baldness than either treatment alone.

In this study, adding low-level light therapy to minoxidil significantly improved hair regrowth and patient satisfaction in treating androgenetic alopecia compared to minoxidil alone.

This review discusses platelet-rich plasma treatment for androgenic alopecia, summarizing current understanding of the disease and the need for standardized clinical trials, but it reports no new results.

This study found that a herbal shampoo and solution were more effective than placebo in reducing hair loss and improving hair growth in participants with androgenetic alopecia and telogen effluvium.

This review discusses advances in molecular biology and genetics related to androgenetic alopecia and reports no new clinical results.

In this study, researchers found that a polyphenolic extract from Annurca apples, high in procyanidin B2, increased hair growth, density, and keratin content in healthy subjects after 2 months of use, and stimulated keratin biosynthesis in vitro.

In this noninferiority study, researchers found that a 0.2% caffeine-based topical liquid was not less effective than 5% minoxidil solution in improving hair growth in men with androgenetic alopecia over six months.

In this study of men with androgenetic alopecia, dutasteride was shown to be more effective than finasteride in increasing hair count and reversing hair miniaturization over 24 weeks, with both treatments displaying similar side effect profiles.

This review discusses various classification systems for patterned hair loss in both sexes and reports no new clinical findings, highlighting the Hamilton-Norwood and Ludwig systems as the most commonly used.

This study evaluated the efficacy and safety of a 5% minoxidil topical foam without propylene glycol in men with androgenic alopecia.

This review discusses the histologic features of nonscarring alopecia and highlights the importance of clinical-pathological correlation for accurate diagnosis, but reports no new clinical results.

This study found that topical minoxidil 5% foam was effective in promoting hair growth in both the frontal and vertex scalp for men with androgenetic alopecia.

This study found that male androgenic alopecia patients using the X5 hair laser device showed a statistically significant increase in hair growth over a 26-week period.

This study found that low-level laser treatment with the HairMax Lasercomb significantly increased terminal hair density in both men and women with pattern hair loss, with no serious adverse events reported.

This pilot study found that a multimodal minoxidil microemulsion with diclofenac and tea tree oil was more effective and safer than minoxidil alone for treating androgenic alopecia over 32 weeks.

This article reviews recent advancements in understanding and treating androgenetic alopecia, focusing on new genetic insights, stem cell roles, and diagnostic tools, without reporting new clinical results.

This article reviews the clinical, psychological, and management aspects of androgenetic alopecia in men, stating that it can be effectively managed by generalist clinicians with pharmacotherapy and surgical advancements.

In this study, decreased expression of BMP2 and ephrin A3 and increased NT-4 gene expression were observed in dermal papilla cells from androgenic alopecia-affected skin, suggesting potential roles in hair growth regulation.

This article reviews the pathogenesis, genetic basis, and recent treatment breakthroughs for androgenetic alopecia but reports no new clinical findings.